MIRM
Mirum Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$100.90
+0.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 618.1M | 521.3M | 336.9M | 186.4M | 77.1M |
| Cost of Revenue | 113.1M | 100.6M | 81.6M | 47.0M | 12.4M |
| Gross Profit | 505.0M | 420.7M | 255.2M | 139.3M | 64.7M |
| Operating Expenses | |||||
| R&D Expense | 282.5M | 186.2M | 140.6M | 102.6M | 106.8M |
| SG&A Expense | 313.8M | 257.0M | 202.2M | 145.9M | 89.1M |
| General & Admin Expense | 81.5M | — | 190.7M | 139.6M | — |
| Selling & Marketing Expense | — | — | 11.5M | 6.3M | — |
| Other Expenses | 16.4M | — | — | — | — |
| Total Operating Expenses | 612.8M | 443.2M | 342.9M | 248.5M | 195.9M |
| Cost and Expenses | 725.7M | 543.4M | 424.5M | 295.5M | 208.3M |
| Operating Income (EBIT) | (107.7M) | (22.1M) | (87.6M) | (109.2M) | (131.2M) |
| Non-Operating | |||||
| Interest Income | 13.9M | 12.7M | 13.8M | 13.7M | 3.9M |
| Interest Expense | 13.4M | 14.4M | 14.3M | 15.1M | 16.0M |
| Net Interest Income | 485.0K | (1.7M) | (519.0K) | (1.4M) | (12.1M) |
| Other Non-Op Income/Expense | (749.9M) | 709.0K | 694.0K | (53.3M) | (10.9M) |
| Non-Operating Income (excl Interest) | 695.1M | (15.1M) | (15.0M) | 38.2M | (5.1M) |
| EBT (Pre-Tax Income) | (857.5M) | (21.4M) | (86.9M) | (162.4M) | (142.1M) |
| Income Tax Expense | 2.7M | 1.9M | 1.0M | 991.0K | (6.4M) |
| Bottom Line | |||||
| Net Income | (860.2M) | (23.4M) | (87.9M) | (163.4M) | (135.7M) |
| Earnings from Cont. Ops | (860.2M) | (23.4M) | (87.9M) | (163.4M) | (135.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (860.2M) | (23.4M) | (87.9M) | (163.4M) | (136.6M) |
| Per Share | |||||
| Basic EPS | ($14.56) | ($0.47) | ($1.85) | ($4.00) | ($4.01) |
| Diluted EPS | ($14.56) | ($0.47) | ($1.85) | ($4.00) | ($4.02) |
| Revenue Per Share | $9.75 | $10.39 | $7.09 | $4.56 | $2.28 |
| Shares | |||||
| Basic Shares Outstanding | 63.4M | 50.2M | 47.5M | 40.9M | 33.8M |
| Diluted Shares Outstanding | 63.4M | 50.2M | 47.5M | 40.9M | 34.0M |
| Profitability Metrics | |||||
| EBITDA | (776.8M) | 17.2M | (49.0M) | (136.5M) | (122.9M) |
| D&A | 25.9M | 24.2M | 23.6M | 10.8M | 3.2M |
| EBIT | (802.7M) | (7.0M) | (72.6M) | (147.3M) | (126.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026